-
Biologics: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Recombinant human bone morphogenetic protein-2 in the treatment of bone fractures
Review
(3120) Views (704) Full article downloads
Authors: Neil Ghodadra, Kern Singh
Published Date September 2008
Volume 2008:2(3) Pages 345 - 354
DOI: http://dx.doi.org/10.2147/BTT.S3394
Neil Ghodadra, Kern Singh
Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois, USA
Abstract: Over one million fractures occur per year in the US and are associated with impaired healing increasing patient morbidity, stress, and economic costs. Despite improvements in surgical technique, internal fixation, and understanding of biologics, fracture healing is delayed or impaired in up to 4% of all fractures. Complications due to impaired fracture healing present therapeutic challenges to the orthopedic surgeon and often lead to chronic functional and psychological disability for the patient. As a result, it has become clinically desirable to augment mechanical fixation with biologic strategies in order to accelerate osteogenesis and promote successful arthrodesis. The discovery of bone morphogenic protein (BMP) has been pivotal in understanding the biology of fracture healing and has been a source of intense clinical research as an adjunct to fracture treatment. Multiple in vitro and in vivo studies in animals have elucidated the complex biologic interactions between BMPs and cellular receptors and have convincingly demonstrated rhBMP-2 to be a safe, effective treatment option to enhance bone healing. Multiple clinical trials in trauma surgery have provided level 1 evidence for the use of rhBMP-2 as a safe and effective treatment of fractures. Human clinical trials have provided further insight into BMP-2 dosage, time course, carriers, and efficacy in fracture healing of tibial defects. These promising results have provided hope that a new biologic field of technology has emerged as a useful adjunct in the treatment of skeletal injuries and conditions.
Keywords: bone morphogenic protein-2, bone fracture, bone healing
Other articles by Dr Kern Singh
Readers of this article also read:
A review of solifenacin in the treatment of urinary incontinence
Treatment of short stature and growth hormone deficiency in children with somatotropin (rDNA origin)
Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines
Emerging hematological targets and therapy for cardiovascular disease: From bench to bedside
Top-down or bottom-up: Contrasting perspectives on psychiatric diagnoses
Rituximab therapy in Greek patients with rheumatoid arthritis
Therapeutic vaccines for malignant brain tumors
Multiple sclerosis: patients’ information sources and needs on disease symptoms and management
Epidemiology and treatment approaches in management of invasive fungal infections
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Journal Indexing
See where all the Dove Press journals are indexed
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




